Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
16 hedge funds and large institutions have $420K invested in Hepion Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
95% more capital invested
Capital invested by funds: $215K → $420K (+$204K)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$8.15M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$985K |
| 3 |
HF
HRT Financial
New York
|
+$160K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$152K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$974 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.6K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$21.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.2K |
| 4 |
Renaissance Technologies
New York
|
-$8.16K |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.37K |
HEPA Hedge Fund Activity: Q1 2025 in Review
16 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2025, worth a combined $420K — up 95% from $215K a quarter earlier.
Fund positioning in HEPA was balanced in Q1 2025: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $8.15M. The largest seller was Vanguard Group, exiting entirely with an estimated $23.6K sold.
- 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $420K of Hepion Pharmaceuticals stock for Q1 2025, up 95% quarter-over-quarter.
- 5 funds opened new Hepion Pharmaceuticals positions in Q1 2025 and 5 closed out, a net change of 0 holders.
- The largest Hepion Pharmaceuticals buyer in Q1 2025 was Sabby Management, an estimated $8.15M added.
- The largest Hepion Pharmaceuticals seller in Q1 2025 was Vanguard Group, an estimated $23.6K sold.
Based on aggregated 13F filings for Q1 2025.